318 related articles for article (PubMed ID: 31280619)
1. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
Mora JS; Genge A; Chio A; Estol CJ; Chaverri D; Hernández M; Marín S; Mascias J; Rodriguez GE; Povedano M; Paipa A; Dominguez R; Gamez J; Salvado M; Lunetta C; Ballario C; Riva N; Mandrioli J; Moussy A; Kinet JP; Auclair C; Dubreuil P; Arnold V; Mansfield CD; Hermine O;
Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):5-14. PubMed ID: 31280619
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
5. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
6. Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients.
Nagata E; Ogino M; Iwamoto K; Kitagawa Y; Iwasaki Y; Yoshii F; Ikeda JE;
PLoS One; 2016; 11(2):e0149509. PubMed ID: 26910108
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
[TBL] [Abstract][Full Text] [Related]
8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
Bensimon G; Lacomblez L; Meininger V
N Engl J Med; 1994 Mar; 330(9):585-91. PubMed ID: 8302340
[TBL] [Abstract][Full Text] [Related]
10. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.
Saccà F; Quarantelli M; Rinaldi C; Tucci T; Piro R; Perrotta G; Carotenuto B; Marsili A; Palma V; De Michele G; Brunetti A; Brescia Morra V; Filla A; Salvatore M
J Neurol; 2012 Jan; 259(1):132-8. PubMed ID: 21706151
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.
Mora JS; Bradley WG; Chaverri D; Hernández-Barral M; Mascias J; Gamez J; Gargiulo-Monachelli GM; Moussy A; Mansfield CD; Hermine O; Ludolph AC
Ther Adv Neurol Disord; 2021; 14():17562864211030365. PubMed ID: 34457038
[TBL] [Abstract][Full Text] [Related]
13. Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials.
Hamad AA; Amer BE
Neurol Sci; 2024 Jul; 45(7):3503-3507. PubMed ID: 38627298
[TBL] [Abstract][Full Text] [Related]
14. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
[TBL] [Abstract][Full Text] [Related]
15. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
Lombardo FL; Spila Alegiani S; Mayer F; Cipriani M; Lo Giudice M; Ludolph AC; McDermott CJ; Corcia P; Van Damme P; Van den Berg LH; Hardiman O; Nicolini G; Vanacore N; Dickie B; Albanese A; Puopolo M;
Trials; 2023 Dec; 24(1):792. PubMed ID: 38053196
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial.
Ahmadi M; Agah E; Nafissi S; Jaafari MR; Harirchian MH; Sarraf P; Faghihi-Kashani S; Hosseini SJ; Ghoreishi A; Aghamollaii V; Hosseini M; Tafakhori A
Neurotherapeutics; 2018 Apr; 15(2):430-438. PubMed ID: 29352425
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.
Lauria G; Dalla Bella E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Fazio R; Filosto M; Giannini F; Granieri E; La Bella V; Logroscino G; Mandrioli J; Mazzini L; Monsurrò MR; Mora G; Pietrini V; Quatrale R; Rizzi R; Salvi F; Siciliano G; Sorarù G; Volanti P; Tramacere I; Filippini G;
J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):879-86. PubMed ID: 25595151
[TBL] [Abstract][Full Text] [Related]
19. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
[TBL] [Abstract][Full Text] [Related]
20. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
